Tag Archives: COPD

Royal Philips announces #BreatheBoldly social initiative on World COPD Day

Philips joins COPD Foundation and family of late Leonard Nimoy in asking the world to #BreatheBoldly on social media to raise COPD awareness AMSTERDAM, 16-Nov-2016 — /EuropaWire/ — On World COPD Day, Royal Philips (NYSE: PHG, AEX: PHIA) is proud … Read the full press release

New analyses confirm Novartis’ Ultibro® Breezhaler® more effective option for patients at risk of COPD flare-ups

Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients’ need for rescue medication and had improved benefit-risk profile compared to Seretide, with … Read the full press release

Boehringer Ingelheim launches campaign to raise public awareness of chronic obstructive pulmonary disease (COPD)

Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death worldwide by 2030 – exceeded only by heart disease and stroke1 By the time most people know they have COPD, … Read the full press release

Boehringer Ingelheim: new data from two trials showing Spiolto® Respimat® provides significant quality of life improvements in patients with moderate to severe COPD

OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients first need maintenance therapy* Head-to-head ENERGITO® study shows superior lung function improvements with Spiolto® Respimat® versus LABA/ICS FDC AMSTERDAM, 29-9-2015 … Read the full press release

Novartis announced positive results from two pivotal Phase III clinical trial programs for QVA149 and NVA237 in patients with COPD

QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderate-to-severe COPD patients[8],[9] In … Read the full press release

AstraZeneca: The Lancet Respiratory Medicine published encouraging safety and efficacy data from Benralizumab Phase II COPD study

Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress LONDON, 8-9-2014 — /EuropaWire/ — AstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa … Read the full press release

AstraZeneca announced it acquired 100% of Redwood City, Calif. based Pearl Therapeutics

28-6-2013 — /europawire.eu/ — AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.  Upon completion of … Read the full press release